MBX Biosciences, Inc. Common Stock (MBX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 64K | 60K | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -64K | -60K | -100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 27.27M | 25.8M | 23.93M | 21.8M | 26.53M | 18.61M | 19.61M | 16.66M | 13.31M | 9.99M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 8.79M | 6.04M | 4.66M | 4.08M | 4.12M | 3.39M | 2.87M | 2.26M | 2.27M | 2.26M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 18.47M | 19.76M | 19.27M | 17.72M | 22.41M | 15.22M | 16.75M | 14.4M | 11.05M | 7.73M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -27.27M | -25.8M | -23.93M | -21.8M | -26.53M | -18.61M | -19.61M | -16.66M | -13.31M | -9.99M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -2.77% | -38.61% | -22% | -30.9% | -99.26% | -86.27% | - | - | - | - |
| EBITDA | -27.2M | -25.73M | -23.88M | -21.74M | -26.45M | -18.55M | -19.54M | -16.59M | -13.27M | -9.95M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -2.83% | -38.72% | -22.21% | -31.03% | -99.4% | -86.45% | - | - | - | - |
| D&A (Non-Cash Add-back) | 64K | 60K | 50K | 61K | 77K | 58K | 75K | 63K | 48K | 41K |
| EBIT | -27.27M | -25.8M | -21.62M | -21.8M | -26.53M | -18.61M | -19.61M | -16.66M | -13.31M | -7.24M |
| Net Interest Income | 3.75M | -7.35M | 2.31M | 2.39M | 2.65M | 3.02M | 1.47M | 801K | 977K | 1.15M |
| Interest Income | 3.75M | -7.35M | 2.31M | 2.39M | 2.65M | 3.02M | 1.47M | 801K | 977K | 1.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.75M | 3.73M | 2.31M | 2.39M | 2.65M | 3.02M | 1.47M | 801K | 977K | 1.15M |
| Pretax Income | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M | -8.84M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M | -8.84M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 1.52% | -41.55% | -19.16% | -22.41% | -93.56% | -76.25% | - | - | - | - |
| Net Income (Continuing) | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M | -8.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.50 | -0.49 | -0.63 | -0.58 | -0.71 | -0.47 | -0.54 | -0.48 | -0.37 | -0.28 |
| EPS Growth % | 29.58% | -4.26% | -16.67% | -20.83% | -91.89% | -67.86% | - | - | - | - |
| EPS (Basic) | -0.50 | -0.49 | -0.63 | -0.58 | -0.71 | -0.47 | -0.54 | -0.48 | -0.37 | -0.28 |
| Diluted Shares Outstanding | 46.58M | 36.51M | 34.2M | 33.45M | 33.41M | 33.39M | 33.39M | 33.38M | 33.38M | 31.85M |
| Basic Shares Outstanding | 46.58M | 36.51M | 34.2M | 33.45M | 33.41M | 33.39M | 33.39M | 33.38M | 33.38M | 31.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |